Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 359

1.

Neonatal Outcomes in Maternal Depression in Relation to Intrauterine Drug Exposure.

Corti S, Pileri P, Mazzocco MI, Mandò C, Moscatiello AF, Cattaneo D, Cheli S, Baldelli S, Pogliani L, Clementi E, Cetin I.

Front Pediatr. 2019 Jul 26;7:309. doi: 10.3389/fped.2019.00309. eCollection 2019.

2.

Impact of Therapeutic Drug Monitoring of Antiretroviral Drugs in Routine Clinical Management of People Living with HIV: a narrative review.

Cattaneo D, Baldelli S, Cozzi V, Clementi E, Marriott DJ, Gervasoni C.

Ther Drug Monit. 2019 Aug 5. doi: 10.1097/FTD.0000000000000684. [Epub ahead of print]

PMID:
31393332
3.

"A pilot study on the non-invasive management of tracheobronchial secretions in tracheostomized patients".

Belli S, Cattaneo D, D'Abrosca F, Prince I, Savio G, Balbi B.

Clin Respir J. 2019 Aug 7. doi: 10.1111/crj.13074. [Epub ahead of print]

PMID:
31390146
4.

UGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemia.

Iurlo A, Bucelli C, Cattaneo D, Levati GV, Viani B, Tavazzi D, Consonni D, Baldini L, Cappellini MD.

Am J Hematol. 2019 Jul 30. doi: 10.1002/ajh.25596. [Epub ahead of print] No abstract available.

PMID:
31364196
5.

INTEGRATING CLINICAL, MORPHOLOGICAL, AND MOLECULAR DATA TO ASSESS PROGNOSIS IN PATIENTS WITH PRIMARY MYELOFIBROSIS AT DIAGNOSIS: A PRACTICAL APPROACH.

Iurlo A, Elli EM, Palandri F, Cattaneo D, Bossi A, Cortinovis I, Bucelli C, Orofino N, Brioschi F, Auteri G, Bianchi P, Fabris S, Isimbaldi G, Sabattini E, Baldini L, Gianelli U.

Hematol Oncol. 2019 Jul 29. doi: 10.1002/hon.2658. [Epub ahead of print]

PMID:
31359447
6.

MOBILITY DISORDERS IN STROKE, PARKINSON'S DISEASE AND MULTIPLE SCLEROSIS: A MULTICENTER CROSS-SECTIONAL STUDY.

Cattaneo D, Gervasoni E, Pupillo E, Bianchi E, Aprile I, Imbimbo I, Russo R, Cruciani A, Jonsdottir J, Agostini M, Beghi E; NEUROFALL Group§.

Am J Phys Med Rehabil. 2019 Jul 22. doi: 10.1097/PHM.0000000000001272. [Epub ahead of print]

PMID:
31343501
7.

How do resistance training and balance and motor control training affect gait performance and fatigue impact in people with multiple sclerosis? A randomized controlled multi-center study.

Callesen J, Cattaneo D, Brincks J, Kjeldgaard Jørgensen ML, Dalgas U.

Mult Scler. 2019 Jul 24:1352458519865740. doi: 10.1177/1352458519865740. [Epub ahead of print]

PMID:
31339460
8.

'Secondary chronic myeloid leukemia': comparison between patients previously exposed or not to chemo- and/or radiotherapy.

Autore F, Sorà F, Chiusolo P, Annunziata M, Iurlo A, Cattaneo D, Galimberti S, Bajer JA, Sica S.

Leuk Lymphoma. 2019 Jul 11:1-3. doi: 10.1080/10428194.2019.1639162. [Epub ahead of print] No abstract available.

PMID:
31294653
9.

No effects of Hypericum-containing complex on dolutegravir plasma trough concentrations: a case report.

Cattaneo D, Fusi M, Gervasoni C.

Eur J Clin Pharmacol. 2019 Jul 1. doi: 10.1007/s00228-019-02714-0. [Epub ahead of print] No abstract available.

PMID:
31263918
10.

Factors influencing balance improvement in multiple sclerosis rehabilitation: A pragmatic multicentric trial.

Cattaneo D, Coote S, Rasova K, Gervasoni E, Groppo E, Prokopiusova T, Reznickova J, Montesano A, Jonsdottir J.

Ann Phys Rehabil Med. 2019 Jun 15. pii: S1877-0657(19)30074-0. doi: 10.1016/j.rehab.2019.05.007. [Epub ahead of print]

PMID:
31212044
11.

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.

Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, De Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Bertolotti L, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Finazzi G.

Leukemia. 2019 Aug;33(8):1996-2005. doi: 10.1038/s41375-019-0487-8. Epub 2019 May 29.

PMID:
31142846
12.

Unexpected analytical interference in isavuconazole UV determination in a child in therapy with lumacaftor/ivacaftor for cystic fibrosis.

Baldelli S, Fusi M, Cozzi V, Clementi E, Faelli NML, Russo M, Colombo C, Cattaneo D.

Clin Chem Lab Med. 2019 May 29. pii: /j/cclm.ahead-of-print/cclm-2019-0192/cclm-2019-0192.xml. doi: 10.1515/cclm-2019-0192. [Epub ahead of print] No abstract available.

PMID:
31141479
13.

Response to Letter Regarding "Minimal Clinically Important Difference of Berg Balance Scale in People With Multiple Sclerosis".

Cattaneo D, Gervasoni E, Montesano A, Jonsdottir J.

Arch Phys Med Rehabil. 2019 Jun;100(6):1191-1192. doi: 10.1016/j.apmr.2019.01.018. No abstract available.

PMID:
31130214
14.

R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma.

Ferreri AJM, Calimeri T, Conte GM, Cattaneo D, Fallanca F, Ponzoni M, Scarano E, Curnis F, Nonis A, Lopedote P, Citterio G, Politi LS, Foppoli M, Girlanda S, Sassone M, Perrone S, Cecchetti C, Ciceri F, Bordignon C, Corti A, Anzalone N.

Blood. 2019 Jul 18;134(3):252-262. doi: 10.1182/blood.2019000633. Epub 2019 May 22.

PMID:
31118164
15.

The Role of New Technologies in Myeloproliferative Neoplasms.

Palumbo GA, Stella S, Pennisi MS, Pirosa C, Fermo E, Fabris S, Cattaneo D, Iurlo A.

Front Oncol. 2019 Apr 26;9:321. doi: 10.3389/fonc.2019.00321. eCollection 2019. Review.

16.

Drug-induced liver steatosis in patients with HIV infection.

Gervasoni C, Cattaneo D, Filice C, Galli M; “Gruppo Italiano Studio-NASH in malattie infettive”.

Pharmacol Res. 2019 Jul;145:104267. doi: 10.1016/j.phrs.2019.104267. Epub 2019 May 8. Review.

PMID:
31077811
17.

Association of HIV Infection with Epilepsy and Other Comorbid Conditions.

Cattaneo D, Giacomelli A, Minisci D, Astuti N, Meraviglia P, Gervasoni C.

AIDS Behav. 2019 May 3. doi: 10.1007/s10461-019-02530-8. [Epub ahead of print]

PMID:
31054031
18.

Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.

Caocci G, Mulas O, Abruzzese E, Iurlo A, Annunziata M, Orlandi EM, Galimberti S, Binotto G, Sgherza N, Luciano L, Martino B, Russo Rossi A, Bonifacio M, Fozza C, Trawinska MM, Cattaneo D, Elena C, Baratè C, De Gregorio F, Molica M, La Nasa G, Foà R, Breccia M.

Ann Hematol. 2019 Aug;98(8):1885-1890. doi: 10.1007/s00277-019-03705-y. Epub 2019 May 1.

PMID:
31044260
19.

Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention.

Caocci G, Mulas O, Bonifacio M, Abruzzese E, Galimberti S, Orlandi EM, Iurlo A, Annunziata M, Luciano L, Castagnetti F, Gozzini A, Stagno F, Binotto G, Pregno P, Albano F, Martino B, Fozza C, Scaffidi L, Trawinska MM, Baratè C, Elena C, Cattaneo D, Scalzulli E, La Nasa G, Foà R, Breccia M.

Int J Cardiol. 2019 Aug 1;288:124-127. doi: 10.1016/j.ijcard.2019.04.051. Epub 2019 Apr 17.

PMID:
31029498
20.

Predictors of hospital-based multidisciplinary rehabilitation effects in persons with multiple sclerosis: a large-scale, single-centre study.

Groppo E, Signori A, Sormani MP, Grosso C, Mantia L, Cattaneo D, Rovaris M.

Mult Scler J Exp Transl Clin. 2019 Apr 16;5(2):2055217319843673. doi: 10.1177/2055217319843673. eCollection 2019 Apr-Jun.

21.

Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.

Iurlo A, Cattaneo D, Gianelli U.

Int J Mol Sci. 2019 Apr 13;20(8). pii: E1839. doi: 10.3390/ijms20081839. Review.

22.

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.

Palandri F, Palumbo GA, Abruzzese E, Iurlo A, Polverelli N, Elli E, Bonifacio M, Bergamaschi M, Martino B, Tiribelli M, Benevolo G, Tieghi A, Sgherza N, Isidori A, Binotto G, Crugnola M, Heidel F, Cavazzini F, Bosi C, Auteri G, Cattaneo D, Foà R, Lemoli RM, Cuneo A, Krampera M, Bartoletti D, Cavo M, Vianelli N, Breccia M, Latagliata R.

Hematol Oncol. 2019 Apr 15. doi: 10.1002/hon.2619. [Epub ahead of print]

PMID:
30985017
23.

Effects of guggulsterones-containing thermogenic complex on elvitegravir plasma concentrations: a case report.

Cattaneo D, Ridolfo A, Baldelli S, Gervasoni C.

Eur J Clin Pharmacol. 2019 Aug;75(8):1177-1178. doi: 10.1007/s00228-019-02677-2. Epub 2019 Apr 13. No abstract available.

PMID:
30982083
24.

Osteolytic Lesions in Primary Myelofibrosis and Effect of Ruxolitinib Therapy: Report of a Case and Literature Review.

Bucelli C, Cattaneo D, Valli VB, Levati GV, Lonati S, Gianelli U, Iurlo A.

Chemotherapy. 2018;63(6):340-344. doi: 10.1159/000497246. Epub 2019 Apr 9.

PMID:
30965327
25.

Assessment of Antiepileptic Drug Concentrations in HIV-Infected versus HIV-Negative Patients: A Retrospective Analysis.

Cattaneo D, Baldelli S, Giacomelli A, Minisci D, Meraviglia P, Astuti N, Fusi M, Cozzi V, Clementi E, Galli M, Gervasoni C.

Clin Pharmacokinet. 2019 Apr 4. doi: 10.1007/s40262-019-00752-6. [Epub ahead of print]

PMID:
30945117
26.

Management of Polypharmacy and Drug-Drug Interactions in HIV Patients: A 2-year Experience of a Multidisciplinary Outpatient Clinic

Gervasoni C, Formenti T, Cattaneo D.

AIDS Rev. 2019;21(1):40-49. doi: 10.24875/AIDSRev.19000035.

PMID:
30899119
27.

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.

Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Sgherza N, Bonifacio M, Annunziata M, Gozzini A, Orlandi EM, Stagno F, Binotto G, Pregno P, Fozza C, Trawinska MM, De Gregorio F, Cattaneo D, Albano F, Gugliotta G, Baratè C, Scaffidi L, Elena C, Pirillo F, Scalzulli E, La Nasa G, Foà R, Breccia M.

Hematol Oncol. 2019 Mar 20. doi: 10.1002/hon.2606. [Epub ahead of print]

PMID:
30892724
28.

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, Rosti G, Castagnetti F, Gugliotta G, Martino B, Gambacorti-Passerini C, Abruzzese E, Elena C, Pregno P, Gozzini A, Capodanno I, Bergamaschi M, Crugnola M, Bocchia M, Galimberti S, Rapezzi D, Iurlo A, Cattaneo D, Latagliata R, Breccia M, Cedrone M, Santoro M, Annunziata M, Levato L, Stagno F, Cavazzini F, Sgherza N, Giai V, Luciano L, Russo S, Musto P, Caocci G, Sorà F, Iuliano F, Lunghi F, Specchia G, Pane F, Ferrero D, Baccarani M, Saglio G.

Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.

29.

Instrumented Version of the Modified Dynamic Gait Index in Patients With Neurologic Disorders.

Anastasi D, Carpinella I, Gervasoni E, Matsuda PN, Bovi G, Ferrarin M, Cattaneo D.

PM R. 2019 Feb 8. doi: 10.1002/pmrj.12137. [Epub ahead of print]

PMID:
30737890
30.

EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis.

Malara A, Gruppi C, Abbonante V, Cattaneo D, De Marco L, Massa M, Iurlo A, Gianelli U, Balduini CL, Tira ME, Muro AF, Chauhan AK, Rosti V, Barosi G, Balduini A.

J Exp Med. 2019 Mar 4;216(3):587-604. doi: 10.1084/jem.20181074. Epub 2019 Feb 7.

PMID:
30733282
31.

Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia.

Raspadori D, Pacelli P, Sicuranza A, Abruzzese E, Iurlo A, Cattaneo D, Gozzini A, Galimberti S, Baratè C, Pregno P, Nicolosi M, Sorà F, Annunziata M, Luciano L, Caocci G, Moretti S, Sgherza N, Fozza C, Russo S, Usala E, Liberati MA, Ciofini S, Trawinska MM, Gozzetti A, Bocchia M.

Cytometry B Clin Cytom. 2019 Jul;96(4):294-299. doi: 10.1002/cyto.b.21764. Epub 2019 Feb 3.

PMID:
30714299
32.

How much does balance and muscle strength impact walking in persons with multiple sclerosis? - A cross-sectional study.

Callesen J, Dalgas U, Brincks J, Cattaneo D.

Mult Scler Relat Disord. 2019 Apr;29:137-144. doi: 10.1016/j.msard.2019.01.034. Epub 2019 Jan 24.

PMID:
30711879
33.

Clinical correlates of 9-hole peg test in a large population of people with multiple sclerosis.

Solaro C, Cattaneo D, Brichetto G, Castelli L, Tacchino A, Gervasoni E, Prosperini L.

Mult Scler Relat Disord. 2019 May;30:1-8. doi: 10.1016/j.msard.2019.01.043. Epub 2019 Jan 28.

PMID:
30710887
34.

Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment.

Cattaneo D, Capetti A, Rizzardini G.

Expert Opin Drug Metab Toxicol. 2019 Mar;15(3):245-252. doi: 10.1080/17425255.2019.1577821. Epub 2019 Feb 11. Review.

PMID:
30704313
35.

Different effects of glucocorticoids on darunavir plasma concentrations.

Cattaneo D, Cheli S, Fusi M, Clementi E, Gervasoni C.

Eur J Clin Pharmacol. 2019 May;75(5):733-735. doi: 10.1007/s00228-019-02626-z. Epub 2019 Jan 9. No abstract available.

PMID:
30627757
36.

Predictors of mobility domain of health-related quality of life after rehabilitation in Parkinson's disease: a pilot study.

Bowman T, Gervasoni E, Parelli R, Jonsdottir J, Ferrarin M, Cattaneo D, Carpinella I.

Arch Physiother. 2018 Dec 27;8:10. doi: 10.1186/s40945-018-0051-2. eCollection 2018.

37.

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.

Palandri F, Palumbo GA, Iurlo A, Polverelli N, Benevolo G, Breccia M, Abruzzese E, Tiribelli M, Bonifacio M, Tieghi A, Isidori A, Martino B, Sgherza N, D'Adda M, Bergamaschi M, Crugnola M, Cavazzini F, Bosi C, Binotto G, Auteri G, Latagliata R, Ibatici A, Scaffidi L, Penna D, Cattaneo D, Soci F, Trawinska M, Russo D, Cuneo A, Semenzato G, Di Raimondo F, Aversa F, Lemoli RM, Heidel F, Reggiani MLB, Bartoletti D, Cavo M, Catani L, Vianelli N.

Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.

PMID:
30502854
38.

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.

Breccia M, Bartoletti D, Bonifacio M, Palumbo GA, Polverelli N, Abruzzese E, Bergamaschi M, Tieghi A, Tiribelli M, Iurlo A, Cavazzini F, Sgherza N, Binotto G, Isidori A, D'Adda M, Crugnola M, Bosi C, Heidel F, Molica M, Scaffidi L, Cattaneo D, Latagliata R, Auteri G, Lemoli RM, Fanin R, Russo D, Aversa F, Cuneo A, Semenzato G, Catani L, Cavo M, Vianelli N, Foà R, Palandri F.

Ann Hematol. 2019 Apr;98(4):889-896. doi: 10.1007/s00277-018-3569-1. Epub 2018 Dec 4.

PMID:
30515542
39.

Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data.

Daskapan A, Tran QTD, Cattaneo D, Gervasoni C, Resnati C, Stienstra Y, Bierman WFW, Kosterink JGW, van der Werf TS, Proost JH, Alffenaar JC, Touw DJ.

Ther Drug Monit. 2019 Feb;41(1):59-65. doi: 10.1097/FTD.0000000000000576.

40.

Instrumental Assessment of Stair Ascent in People With Multiple Sclerosis, Stroke, and Parkinson's Disease: A Wearable-Sensor-Based Approach.

Carpinella I, Gervasoni E, Anastasi D, Lencioni T, Cattaneo D, Ferrarin M.

IEEE Trans Neural Syst Rehabil Eng. 2018 Dec;26(12):2324-2332. doi: 10.1109/TNSRE.2018.2881324. Epub 2018 Nov 14.

PMID:
30442611
41.

Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.

Giacomelli A, Riva A, Falvella FS, Oreni ML, Cattaneo D, Cheli S, Renisi G, Di Cristo V, Lupo A, Clementi E, Rusconi S, Galli M, Ridolfo AL.

BMC Infect Dis. 2018 Nov 12;18(1):556. doi: 10.1186/s12879-018-3462-5.

42.

Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor.

Cattaneo D, Gervasoni C.

Eur J Drug Metab Pharmacokinet. 2019 Jun;44(3):319-327. doi: 10.1007/s13318-018-0526-2.

PMID:
30387005
43.

Clinical validity of novel postural stabilization experimental indices based on hyperbolic transformation.

Rabuffetti M, Lencioni T, Cattaneo D, Zemp DD, Quadri P, Ferrarin M.

Gait Posture. 2019 Jan;67:147-150. doi: 10.1016/j.gaitpost.2018.09.024. Epub 2018 Sep 25.

PMID:
30380504
44.

A three-in-one, long-acting, nanosuspension reformulation of off-patent antiretrovirals for low-income and middle-income countries.

Cattaneo D, Perno CF, Rizzardini G.

AIDS. 2018 Nov 13;32(17):2625-2627. doi: 10.1097/QAD.0000000000001970. No abstract available.

PMID:
30379688
45.

Responsiveness and meaningful improvement of mobility measures following MS rehabilitation.

Baert I, Smedal T, Kalron A, Rasova K, Heric-Mansrud A, Ehling R, Elorriaga Minguez I, Nedeljkovic U, Tacchino A, Hellinckx P, Adriaenssens G, Stachowiak G, Gusowski K, Cattaneo D, Borgers S, Hebert J, Dalgas U, Feys P.

Neurology. 2018 Nov 13;91(20):e1880-e1892. doi: 10.1212/WNL.0000000000006532. Epub 2018 Oct 17.

PMID:
30333161
46.

Intensive Multimodal Training to Improve Gait Resistance, Mobility, Balance and Cognitive Function in Persons With Multiple Sclerosis: A Pilot Randomized Controlled Trial.

Jonsdottir J, Gervasoni E, Bowman T, Bertoni R, Tavazzi E, Rovaris M, Cattaneo D.

Front Neurol. 2018 Sep 28;9:800. doi: 10.3389/fneur.2018.00800. eCollection 2018.

47.

Modified Functional Walking Categories and participation in people with multiple sclerosis.

Bertoni R, Jonsdottir J, Feys P, Lamers I, Cattaneo D.

Mult Scler Relat Disord. 2018 Nov;26:11-18. doi: 10.1016/j.msard.2018.08.031. Epub 2018 Aug 31.

PMID:
30212768
48.

Early Treatment with Quinidine in 2 Patients with Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) Due to Gain-of-Function KCNT1 Mutations: Functional Studies, Clinical Responses, and Critical Issues for Personalized Therapy.

Dilena R, DiFrancesco JC, Soldovieri MV, Giacobbe A, Ambrosino P, Mosca I, Galli MA, Guez S, Fumagalli M, Miceli F, Cattaneo D, Darra F, Gennaro E, Zara F, Striano P, Castellotti B, Gellera C, Varesio C, Veggiotti P, Taglialatela M.

Neurotherapeutics. 2018 Oct;15(4):1112-1126. doi: 10.1007/s13311-018-0657-9.

PMID:
30112700
49.

Counteracting Postural Perturbations Through Body Weight Shift: a Pilot Study Using a Robotic Platform in Subjects with Parkinson's Disease.

Carpinella I, Nardone A, Bonora G, Bowman T, Cattaneo D, Rabuffetti M, Ferrarin M.

IEEE Trans Neural Syst Rehabil Eng. 2018 Aug 2. doi: 10.1109/TNSRE.2018.2862463. [Epub ahead of print]

PMID:
30072335
50.

Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution?

Cattaneo D, Giacomelli A, Gervasoni C.

Obesity (Silver Spring). 2018 Aug;26(8):1251-1252. doi: 10.1002/oby.22240. Epub 2018 Aug 1.

Supplemental Content

Loading ...
Support Center